SCB
REGN icon

Saudi Central Bank’s Regeneron Pharmaceuticals REGN Stock Holding History

Saudi Central Bank’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.95M Buy
+3,812
New +$2.92M 0.06% 147
2025
Q2 		– Sell
-43
Closed -$27.3K – 437
2025
Q1 		$27.3K Buy
+43
New +$29.6K 0.14% 136

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Saudi Central Bank's REGN Position: Q1 2026 in Review

Saudi Central Bank opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 3,812 shares worth $2.95M. The stake represents 0.06% of the portfolio and ranks #147 among its holdings. This is a return to the name: Saudi Central Bank previously reported a position in REGN as recently as Q1 2025.

Saudi Central Bank first reported a position in REGN in Q1 2025 and has held it in 2 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Saudi Central Bank held 3,812 shares of Regeneron Pharmaceuticals worth $2.95M as of Q1 2026.
  • Regeneron Pharmaceuticals was a new Saudi Central Bank position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.06% of Saudi Central Bank's portfolio in Q1 2026, its #147 holding.
  • Saudi Central Bank first reported a position in Regeneron Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Saudi Central Bank's 13F filing for Q1 2026, filed 15 May 2026.